Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Abstract:
rrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data on the development of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), at the 28th Annual FSHD Society International Research Congress. Arrowhead intends to file for regulatory clearance in the third quarter of 2021 to begin clinical studies of ARO-DUX4.

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Pasadena. CA | Posted on June 25th, 2021

James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: “Preclinical development of ARO-DUX4 has produced very promising results that we believe strongly support advancement into clinical testing. In our preclinical studies in relevant models, ARO-DUX4 achieved deep knockdown of DUX4 and its target genes. Importantly, in a transgenic mouse model of FSHD, treatment with ARO-DUX4 prevented and reversed tamoxifen-induced increases in DUX4 and DUX4 target gene expression. In addition, ARO-DUX4 prevented and reversed DUX4-induced body weight loss, muscle fibrosis, and rotarod performance loss. Collectively, these preclinical results suggest that ARO-DUX4 achieved good target engagement, which led to a downstream beneficial physiological change. We look forward to initiating our clinical program and translating these results into humans. A significant unmet need exists in FSHD, an indication with no currently available treatments.”

Preclinical data demonstrated that Arrowhead’s Targeted RNAi Molecule (TRiM™) muscle delivery platform can achieve functional delivery to various types of skeletal muscle. Using RNAscope to detect RNAi, after a single 3 mg/kg intravenous (IV) dose in a mouse, 76-99% of myofibers in gastrocnemius contained TRiM™ RNAi. In addition, nonhuman primates receiving three doses of 10 mg/kg (day 1, 7, and 28) of a TRiM™ RNAi targeting myostatin achieved 79% serum myostatin knockdown with a greater than 70% reduction still being observed at week 12.

ARO-DUX4 also achieved dose-dependent knockdown of DUX4 and a deep reduction of DUX4 target gene expression in differentiated FSHD patient-derived myotubes. Additionally, ARO-DUX4 was evaluated in a transgenic FSHD-like mouse model, which has muscle-specific expression of human DUX4 and increased expression of DUX4 target genes. These animals develop a FSHD-like muscle phenotype which includes functional loss. In this model, ARO-DUX4 treatment:

Prevented and reversed a tamoxifen-induced increase in DUX4 and DUX4 target gene expression
Prevented DUX4-induced body weight loss
Reversed DUX4-induced body weight loss by day 17 allowing a return to baseline body weight by day 22
Prevented and reversed muscle fibrosis
Prevented rotarod performance loss
Reversed rotarod performance loss by day 15
A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

FSHD is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. As DUX4 expression is recognized as the cause of muscle pathology in FSHD patients, Arrowhead believes that the selective targeting and knockdown of DUX4 using RNAi may prevent or reverse downstream myotoxicity and lead to muscle repair and improvement in muscle function in patients. There are currently no effective treatments specifically for FSHD.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Getting to the root of tooth replantation challenges: Researchers from Tokyo Medical and Dental University (TMDU) report a delivery system that promotes healing in tooth replantation in rats September 17th, 2021

Researchers reveal multi-path mechanism in electrochemical CO2 reduction September 17th, 2021

Scientists demonstrate pathway to forerunner of nanotubes that could lead to widespread industrial fabrication September 17th, 2021

Silver nanoparticles boost performance of microbial fuel cells September 17th, 2021

Govt.-Legislation/Regulation/Funding/Policy

A simple way to get complex semiconductors to assemble themselves: Much like crystallizing rock candy from sugar syrup, the new method grows 2D perovskites precisely layered with other 2D materials to produce crystals with a wide range of electronic properties September 17th, 2021

Scientists demonstrate pathway to forerunner of nanotubes that could lead to widespread industrial fabrication September 17th, 2021

Lehigh University to lead ‘integrative partnerships’ for multi-university research collaboration in advanced optoelectronic material development: 5-year, $25 million NSF investment in IMOD, a revolutionary center for optoelectronic, quantum technologies September 10th, 2021

Stretching the capacity of flexible energy storage September 10th, 2021

Possible Futures

New nano particles suppress resistance to cancer immunotherapy September 17th, 2021

New physics research reveals fresh complexities about electron behavior in materials September 17th, 2021

Scientists demonstrate pathway to forerunner of nanotubes that could lead to widespread industrial fabrication September 17th, 2021

Silver nanoparticles boost performance of microbial fuel cells September 17th, 2021

Nanomedicine

New nano particles suppress resistance to cancer immunotherapy September 17th, 2021

Getting to the root of tooth replantation challenges: Researchers from Tokyo Medical and Dental University (TMDU) report a delivery system that promotes healing in tooth replantation in rats September 17th, 2021

Engineering various sources of loss provides new features for perfect light absorption: "Loss is ubiquitous in nature, and by better understanding it, we make it more useful" September 10th, 2021

Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021

Announcements

Getting to the root of tooth replantation challenges: Researchers from Tokyo Medical and Dental University (TMDU) report a delivery system that promotes healing in tooth replantation in rats September 17th, 2021

Researchers reveal multi-path mechanism in electrochemical CO2 reduction September 17th, 2021

Scientists demonstrate pathway to forerunner of nanotubes that could lead to widespread industrial fabrication September 17th, 2021

Silver nanoparticles boost performance of microbial fuel cells September 17th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences September 1st, 2021

UVA Engineering researchers join quest to demonstrate photonic systems-on-chip: Future applications include faster, more efficient data centers and next-generation millimeter-wave wireless communication July 30th, 2021

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress June 24th, 2021

NSS Fetes JPL’s Rob Manning and Robert Braun at the Online 2021 International Space Development Conference: This Year’s Virtual Conference Streams Free to All Beginning Thursday June 24th, 2021

Nanobiotechnology

New nano particles suppress resistance to cancer immunotherapy September 17th, 2021

Getting to the root of tooth replantation challenges: Researchers from Tokyo Medical and Dental University (TMDU) report a delivery system that promotes healing in tooth replantation in rats September 17th, 2021

Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021

Imaging single spine structural plasticity at the nanoscale level: Researchers at the Max Planck Florida Institute for Neuroscience (MPFI) have developed a new imaging technique capable of visualizing the dynamically changing structure of dendritic spines with unprecedented resol September 3rd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project